Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers [2] - The company will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025 [1] - Dr. Marc H. Hedrick, President and CEO of Plus Therapeutics, will engage in a fireside chat at the conference, available on demand for registered investors starting September 5 [2] Company Overview - Plus Therapeutics is headquartered in Houston, Texas, and specializes in targeted radiotherapeutics aimed at difficult-to-treat CNS cancers [2] - The company is advancing a pipeline of product candidates, with lead programs targeting leptomeningeal metastases and recurrent glioblastoma [2] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [2]